New Edge Advisors, LLC Biocryst Pharmaceuticals Inc Transaction History

New Edge Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$6.96 - $8.81 $28,382 - $35,927	-4,078 Reduced 99.27%	30 $0
Q1 2023 May 12, 2023	SELL	$7.94 - $11.84 $33,482 - $49,929	-4,217 Reduced 50.65%	4,108 $34,000
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $87,412 - $118,215	8,325 New	8,325 $95,000
Q2 2022 Aug 09, 2022	SELL	$7.89 - $17.88 $90,695 - $205,530	-11,495 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$11.56 - $19.76 $12,981 - $22,190	-1,123 Reduced 8.9%	11,495 $187,000
Q4 2021 Feb 17, 2022	SELL	$11.18 - $15.46 $18,301 - $25,308	-1,637 Reduced 11.48%	12,618 $175,000
Q3 2021 Oct 29, 2021	BUY	$14.21 - $17.65 $27,908 - $34,664	1,964 Added 15.98%	14,255 $205,000
Q2 2021 Jul 22, 2021	SELL	$9.5 - $17.24 $1,092 - $1,982	-115 Reduced 0.93%	12,291 $194,000
Q1 2021 Apr 26, 2021	BUY	$7.37 - $13.61 $91,432 - $168,845	12,406 New	12,406 $126,000
Q4 2020 Jan 27, 2021	SELL	$3.37 - $8.61 $80,880 - $206,640	-24,000 Closed	0 $0
Q3 2020 Nov 03, 2020	BUY	$3.43 - $5.53 $82,320 - $132,720	24,000 New	24,000 $82,000

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on New Edge Advisors, LLC with notifications on news.